GSK's Jemperli Receives FDA Priority Review for Rectal Cancer Treatment

GSK's cancer therapy, Jemperli (dostarlimab), has been granted priority review by the U.S. FDA for its potential use in treating rectal cancer. This designation accelerates the regulatory process, potentially making a new treatment option available sooner for patients with this type of cancer.